2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2420

Azathioprine for Glucocorticoid Resistant Non-Renal Henoch-Schönlein Purpura

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2394

B-Flow Imaging of Synovial Tissue in Osteoarthritis

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2460

B10 Cells May be Involved in Controlling Disease Activity in Polyarticular Juvenile Idiopathic Arthritis Patients

Pediatric Rheumatology - Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2806

Bacterial Skin Microbiome in Psoriatic Arthritis Ã¢â‚¬â€œ Pilot Data from Psoriatic Plaques on Dry Skin Sites from Patients with Psoriasis (PsC) and Psoriatic Arthritis (PsA)

Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 2498

Barriers to Appointment Compliance and the Effect of Reminder Phone Calls on Lupus Clinic Show Rate in an Underserved Community

Quality Measures and Quality of Care Poster Session

9:00AM-11:00AM: Abstract Number: 2723

Basal STAT5 Signaling Is Elevated in Multiple Peripheral Blood Cell Subsets in Rheumatoid Arthritis and Is Markedly Downregulated By IFN-Î³ in T Lymphocytes

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2728

Baseline Characteristics and Changes in Disease Activity at 12 Months in Patients Treated with Abatacept Versus Other Biologic Disease-Modifying Antirheumatic Drugs in Clinical Practice Setting

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2876

Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2882

Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster III: Therapy

9:00AM-11:00AM: Abstract Number: 2399

Baseline Fibulin3 Concentrations Are Associated with Incidence of Clinical Knee OA after 30 Months in Overweight and Obese Women

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2938

Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2309

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2779

Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2727

BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2789

Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome

Sjögren's Syndrome: Translational Insights into Sjögren's Syndrome

«Previous Page
1
…
7
8
9
10
11
…
72
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].